Literature DB >> 17442230

Soft tissue sarcoma.

George D Demetri1, Laurence H Baker, Robert S Benjamin, Ephraim S Casper, Ernest U Conrad, Gina Z D'Amato, Thomas F DeLaney, David S Ettinger, Robert Heck, Martin J Heslin, Ray J Hutchinson, Charlotte D Jacobs, Krystyna Kiel, William G Kraybill, G Douglas Letson, Richard J O'Donnell, I Benjamin Paz, John Pfeifer, Raphael E Pollock, R Lor Randall, Aaron R Sasson, Karen D Schupak, Douglas S Tyler, Margaret von Mehren, Jeffrey Wayne.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17442230     DOI： 10.6004/jnccn.2007.0034

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  11 in total

1.  Surgical margin status and prognosis of gastrointestinal stromal tumor.

Authors:  António M Gouveia; Amadeu P Pimenta; Ana F Capelinha; Dionísio de la Cruz; Paula Silva; José M Lopes
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

2.  Updates on the management of gastrointestinal stromal tumors.

Authors:  Zubin M Bamboat; Ronald P Dematteo
Journal:  Surg Oncol Clin N Am       Date:  2012-04       Impact factor: 3.495

3.  Different sites and prognoses of gastrointestinal stromal tumors of the stomach: report of 187 cases.

Authors:  Hai Huang; Yan-Xue Liu; Zhong-Li Zhan; Han Liang; Pu Wang; Xiu-Bao Ren
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

4.  Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up.

Authors:  Margherita Nannini; Guido Biasco; Maria Caterina Pallotti; Monica Di Battista; Donatella Santini; Paola Paterini; Alessandra Maleddu; Anna Mandrioli; Cristian Lolli; Maristella Saponara; Valerio Di Scioscio; Maurizio Zompatori; Fausto Catena; Pietro Fusaroli; Angelo Paolo Dei Tos; Maria Abbondanza Pantaleo
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

5.  Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.

Authors:  Jérôme Fayette; Nicolas Penel; Christine Chevreau; Jean-Yves Blay; Didier Cupissol; Antoine Thyss; Cécile Guillemet; Maria Rios; Frédéric Rolland; Pierre Fargeot; Jacques Olivier Bay; Simone Mathoulin-Pelissier; Jean Michel Coindre; Binh Bui-Nguyen
Journal:  Invest New Drugs       Date:  2009-01-16       Impact factor: 3.850

6.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Authors:  Martee L Hensley; John A Blessing; Robert Mannel; Peter G Rose
Journal:  Gynecol Oncol       Date:  2008-06       Impact factor: 5.482

Review 7.  Management of resectable gastrointestinal stromal tumor.

Authors:  Umer I Chaudhry; Ronald P DeMatteo
Journal:  Hematol Oncol Clin North Am       Date:  2009-02       Impact factor: 3.722

8.  Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network.

Authors:  Clara Chen; Rohit Borker; James Ewing; Wan-Yu Tseng; Michelle D Hackshaw; Shanmugapriya Saravanan; Rahul Dhanda; Eric Nadler
Journal:  Sarcoma       Date:  2014-01-12

9.  Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report.

Authors:  Kananathan Ratnavelu; Baskar Subramani; Chithra Ramanathan Pullai; Kohila Krishnan; Sheela Devi Sugadan; Manjunath Sadananda Rao; Abhi Veerakumarasivam; Xuewen Deng; Terunuma Hiroshi
Journal:  Oncol Lett       Date:  2013-03-12       Impact factor: 2.967

10.  Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors.

Authors:  Keith M Skubitz; Stefan Pambuccian; J Carlos Manivel; Amy P N Skubitz
Journal:  J Transl Med       Date:  2008-05-06       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.